Bicara Therapeutics (BCAX) Cantor Global Healthcare Conference 2025 summary

Company overview and lead program

• Focuses on targeted tumor modulation with a lead EGFR TGF-beta trap program, ficerafusp alfa, in clinical development since 2020.

• Currently enrolling a pivotal study for potential accelerated approval in HPV-negative recurrent/metastatic head and neck cancer.

Market landscape and unmet need

• Head and neck cancer has a large unmet need, with 30,000 U.S. patients annually and higher global incidence.

• HPV-negative patients represent 80% of the U.S. and up to 95% in Europe/Asia; these patients respond poorly to current immunotherapies.

• Standard of care, pembrolizumab, yields a median OS of 9 months in HPV-negative cases.

Mechanism of action and clinical rationale

• Ficerafusp alfa targets both EGFR and TGF-beta, addressing the highly immunosuppressive, EGFR-overexpressing, and TGF-beta-rich tumor microenvironment in HPV-negative disease.

• Translational data show tumor TGF-beta inhibition, immune cell reactivation, and deep tumor responses.